Katherine Miller
Optometrist · Rehoboth Beach, DENPI 1932360856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alcon at 28.2% of the total. 2025 is the largest year on record at $295, 2.3 times the $128 reported in 2019.
Across 49 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$278
- Coopervision Inc.$145
- Tarsus Pharmaceuticals, Inc.$124
- Sun Pharmaceutical Industries Inc.$116
- Kala Pharmaceuticals, Inc.$55
- Dompe US, Inc.$44
- plus $227 from 8 others
What the payments were for
- Food & beverage$96998%
- Gifts$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 14 | $278 |
| Coopervision Inc. | 8 | $145 |
| Tarsus Pharmaceuticals, Inc. | 5 | $124 |
| Sun Pharmaceutical Industries Inc. | 6 | $116 |
| Kala Pharmaceuticals, Inc. | 3 | $55 |
| Dompe US, Inc. | 2 | $44 |
| Lombart Brothers, Inc. | 1 | $38 |
| Johnson & Johnson Vision Care, Inc. | 2 | $37 |
| Harrow Eye, LLC | 2 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $32 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Novartis | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
How this compares
$988 in reported general payments places this provider in the 60th percentile of 146 optometrist providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 14 | $22,290 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $4,802 |
| Latanoprost | 43 | $481 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $184 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $93 |
| Timolol Maleate | 19 | $75 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Rehoboth Beach
- Jennifer TuranoWilmington$42K
- Laura GoldbergWilmington$17K
- Linen PokNewark$5K
- Lea MenearWilmington$4K
- Lorna SimmermanWilmington$4K
- Kimberly BristowNewark$4K
- Alissa LongWilmington$4K
- Scott TucciWilmington$3K
- Nadine HermannNewark$3K
- Sarah Nowicki-DuczeminskiWilmington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.